NexWave Capital Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

NexWave Capital Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,310	Closed	-$290K	–	48
2021 Q3	$290K	Buy	+2,310	New	+$297K	0.75%	33

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

NexWave Capital Partners's XBI Position: Q4 2021 in Review

NexWave Capital Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2021, closing a stake of 2,310 shares — an estimated $290K sold.

NexWave Capital Partners first reported a position in XBI in Q3 2021 and held it in 1 quarter. The position peaked at $290K in Q3 2021. 700 funds tracked by Wall St. Rank hold XBI as of Q4 2021.

NexWave Capital Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2021 after selling out during the quarter.
NexWave Capital Partners sold 2,310 State Street SPDR S&P Biotech ETF shares in Q4 2021, an estimated $290K.
NexWave Capital Partners first reported a position in State Street SPDR S&P Biotech ETF in Q3 2021 and held it in 1 quarter.
NexWave Capital Partners's State Street SPDR S&P Biotech ETF position peaked at $290K in Q3 2021.
700 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2021.

Based on NexWave Capital Partners's 13F filing for Q4 2021, filed 10 Feb 2022.